Long-Term Safety of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1) Antibody SHP647 in Ulcerative Colitis: An Open-Label Extension Study (TURANDOT II)
Walter Reinisch(Medical University of Vienna), Séverine Vermeire(KU Leuven), Bruce Salzberg(Atlanta Gastroenterology Associates), Dino Tarabar(Military Medical Academy), Caleb Bliss(Takeda (United States)), William J. Sandborn(University of San Diego), Martina Goetsch(Pfizer (United States)), Tomáš Vaňásek, Fabio Cataldi(Pfizer (United States)), Silvio Danese(IRCCS Ospedale San Raffaele), Xavier Hébuterne(Université Côte d'Azur), Paul Hellstern(Clinical Research Atlanta), Miles Sparrow(Alfred Health), Joo Sung Kim(Seoul National University), Kenneth J. Gorelick, Miloš Greguš, Maria Kłopocka(Nicolaus Copernicus University)
Cited by 0
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k